Aptevo Therapeutics Stock Scheduled to Reverse Split on Tuesday, December 30th (NASDAQ:APVO)

Shares of Aptevo Therapeutics Inc. (NASDAQ:APVO) are scheduled to reverse split before the market opens on Tuesday, December 30th. The 1-18 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the market closes on Monday, December 29th.

Aptevo Therapeutics Stock Performance

Shares of NASDAQ APVO traded down $0.32 during mid-day trading on Friday, hitting $0.61. 14,545,851 shares of the stock traded hands, compared to its average volume of 1,063,643. The company has a market cap of $10.23 million, a price-to-earnings ratio of -0.01 and a beta of 1.41. The stock has a fifty day moving average price of $1.30 and a 200-day moving average price of $2.02. Aptevo Therapeutics has a 52 week low of $0.50 and a 52 week high of $109.80.

Aptevo Therapeutics (NASDAQ:APVO) last issued its quarterly earnings results on Thursday, November 6th. The biotechnology company reported ($2.23) earnings per share for the quarter, missing the consensus estimate of ($2.09) by ($0.14). As a group, sell-side analysts predict that Aptevo Therapeutics will post -15.84 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the stock. Weiss Ratings reissued a “sell (e)” rating on shares of Aptevo Therapeutics in a research note on Monday. Roth Capital raised Aptevo Therapeutics to a “strong-buy” rating in a research report on Tuesday, September 16th. Finally, Zacks Research raised Aptevo Therapeutics to a “hold” rating in a research report on Thursday, September 18th. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Aptevo Therapeutics has a consensus rating of “Hold”.

Institutional Investors Weigh In On Aptevo Therapeutics

An institutional investor recently bought a new position in Aptevo Therapeutics stock. Virtu Financial LLC acquired a new position in Aptevo Therapeutics Inc. (NASDAQ:APVO) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 38,282 shares of the biotechnology company’s stock, valued at approximately $56,000. Virtu Financial LLC owned about 1.16% of Aptevo Therapeutics as of its most recent SEC filing. Hedge funds and other institutional investors own 8.06% of the company’s stock.

About Aptevo Therapeutics

Aptevo Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Seattle, Washington, focused on the discovery and development of novel immunotherapies for oncology and autoimmune diseases. Founded in 2012 as a spin-off from Emergent BioSolutions, the company builds on expertise in protein engineering and translational research to create targeted biologics that engage the body’s immune system.

The company’s core technologies include the ADAPTIR platform, which enables the design of bispecific and multispecific protein scaffolds with customizable binding domains, and the KNOCKOUT platform, which incorporates non-natural amino acids to enhance therapeutic properties such as stability and half-life.